Trial Profile
A Multi-center, Randomized, Double-blind, Parallel Control Clinical Trial to Assess the Similarity of the Safety and Pharmacokinetics of TQB2303 in Combination With Rituximab to Patients With AggressiveCD20 Positive Non-Hodgkin's Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 14 Mar 2018 New trial record